Prognostic significance of Dicer expression in ovarian cancer - Link to global microRNA changes and oestrogen receptor expression

Journal of Pathology

Volumn 220, Issue 3, 2010, Pages 382-391

  Faggad, Areeg ^a,c   Budczies, Jan ^a   Tchernitsa, Oleg ^a   Darb Esfahani, Silvia ^a   Sehouli, Jalid ^a   Müller, Berit M ^a   Wirtz, Ralph ^b   Chekerov, Radoslav ^a   Weichert, Wilko ^a   Sinn, Bruno ^a   Mucha, Christin ^a   Elwali, Nasr E ^c   Schäfer, Reinhold ^a   Dietel, Manfred ^a   Denkert, Carsten ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b SIEMENS AG   (Germany)

^c UNIVERSITY OF GEZIRA   (Sudan)

Author keywords

Dicer; microRNA; Oestrogen receptor; Ovarian cancer; Prognosis

Indexed keywords

DICER; ESTROGEN RECEPTOR; MICRORNA;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MICROARRAY ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE EXPRESSION PROFILING; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICRORNAS; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; RECEPTORS, ESTROGEN; RIBONUCLEASE III; RNA, NEOPLASM; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 75749131999     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2658     Document Type: Article

References (43)

1. Ozols RF. Challenges for chemotherapy in ovarian cancer. Ann Oncol 2006;17(suppl 5):v181-187.
2. Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, et al. Focus on epithelial ovarian cancer. Cancer Cell 2004;5:19-24.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
4. Sager R. Expression genetics in cancer: shifting the focus from DNA to RNA. Proc Natl Acad Sci USA 1997;94:952-955.
5. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-297.
6. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004;5:522-531.
7. Ambros V. MicroRNAs: tiny regulators with great potential. Cell 2001;107:823-826.
8. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006;103:2257-2261.
9. Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 2006;66:7390-7394.
10. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-838.
11. Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen C, et al. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res 2007;67:2456-2468.
12. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 2007;39:673-677.
13. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007;67:8699-8707.
14. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J 2004;23:4051- 4060.
15. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003;425:415-419.
16. Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 2003;17:3011- 3016.
17. Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U. Nuclear export of microRNA precursors. Science 2004;303:95-98.
18. Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001;409:363-366.
19. Hutvagner G, McLachlan J, Pasquinelli AE, Balint E, Tuschl T, Zamore PD. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science 2001;293:834-838.
20. Hammond SM, Boettcher S, Caudy AA, Kobayashi R, Hannon GJ. Argonaute2, a link between genetic and biochemical analyses of RNAi. Science 2001;293:1146-1150.
21. Meister G, Tuschl T. Mechanisms of gene silencing by doublestranded RNA. Nature 2004;431:343-349.
22. Zamore PD, Haley B. Ribo-gnome: the big world of small RNAs. Science 2005;309:1519-1524.
23. Wiemer EA. The role of microRNAs in cancer: no small matter. Eur J Cancer 2007;43:1529-1544.
24. Nelson P, Kiriakidou M, Sharma A, Maniataki E, Mourelatos Z. The microRNA world: small is mighty. Trends Biochem Sci 2003;28:534-540.
25. Sehouli J, Konsgen D, Mustea A, Oskay-Ozcelik G, Katsares I, Weidemann H, et al. ['IMO' - intraoperative mapping of ovarian cancer]. Zentralbl Gynakol 2003;125:129-135.
26. Faggad A, Darb-Esfahani S, Wirtz R, Sinn B, Sehouli J, Konsgen D, et al. Expression of multidrug resistance-associated protein 1 in invasive ovarian carcinoma: implication for prognosis. Histopathology 2009;54:657-666.
27. Darb-Esfahani S, Wirtz R, Sinn B, Budczies J, Noske A, Weichert W, et al. Estrogen receptor 1 mRNA is a prognostic factor in ovarian carcinoma: determination by kinetic PCR in formalin-fixed paraffin-embedded tissue. Endocr Relat Cancer 2009;[Epub ahead of print].
28. Denkert C, Budczies J, Darb-Esfahani S, Gyorffy B, Sehouli J, Konsgen D, et al. A prognostic gene expression index in ovarian cancer - validation across different independent data sets. J Pathol 2009;218:273-280.
29. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 2008;359:2641-2650.
30. Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A, et al. MicroRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA 2006;103:9136-9141.
31. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008;68:425-433.
32. Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 2008;14:2690-2695.
33. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005;65:7065-7070.
34. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9:189-198.
35. Michael MZ, SM OC, van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 2003;1:882-891.
36. Wu W, Lin Z, Zhuang Z, Liang X. Expression profile of mammalian microRNAs in endometrioid adenocarcinoma. Eur J Cancer Prev 2009;18:50-55.
37. Laios A, O'Toole S, Flavin R, Martin C, Kelly L, Ring M, et al. Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer 2008;7:35.
38. Karube Y, Tanaka H, Osada H, Tomida S, Tatematsu Y, Yanagisawa K, et al. Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci 2005;96:111-115.
39. Chiosea S, Jelezcova E, Chandran U, Luo J, Mantha G, Sobol RW, et al. Overexpression of Dicer in precursor lesions of lung adenocarcinoma. Cancer Res 2007;67:2345-2350.
40. Zheng ZH, Sun XJ, Fu WN, Guan Y, Gao F, Wang Y, et al. Decreased expression of DICER1 in gastric cancer. Chin Med J (Engl) 2007;120:2099-2104.
41. Irvin-Wilson CV, Chaudhuri G. Alternative initiation and splicing in dicer gene expression in human breast cells. Breast Cancer Res 2005;7:R563-569.
42. Izquierdo M: Short interfering RNAs as a tool for cancer gene therapy. Cancer Gene Ther 2005;12:217-227.
43. Martin SE, Caplen NJ. Applications of RNA interference in mammalian systems. Annu Rev Genom Hum Genet 2007;8:81-108.